Latest Breaking News On - Reduced mortality with treatment - Page 1 : comparemela.com

Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis

Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongZhong hua neiJinzij wuClin gastroenterol hepatolHong kong stock exchangeAscletis pharma incPrnewswire gannex pharma co ltdChinese rheumatology associationAscletis pharmaFibroblast growth factorBiliary cholangitisAmerican associationLiver diseasesPlacebo controlled trialObeticholic acid

Gannex Announces First Subject Dosed in the U S Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis - Press Release

Enrollment of the total 12 subjects is expected to be completed in August 2022 The DDI study on ASC42 in the U.S. is expected to be completed by

United statesHong kongClin gastroenterol hepatolJinzij wuGastroenterol hepatolGannex pharma co ltdHong kong stock exchangeEuropean unionAscletis pharma incAscletis pharmaAsian pacific associationObeticholic acidPrimary biliary cholangitisReduced mortality with treatmentBiliary cholangitisAmerican association

Gannex Announces First Subject Dosed in the U S Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

/PRNewswire/ Gannex Pharma Co., Ltd. ("Gannex"), a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) today announces that it has completed the first.

United statesHong kongClin gastroenterol hepatolJinzij wuGastroenterol hepatolHong kong stock exchangeEuropean unionAscletis pharma incPrnewswire gannex pharma co ltdAscletis pharmaAsian pacific associationObeticholic acidPrimary biliary cholangitisReduced mortality with treatmentBiliary cholangitisAmerican association

Gannex Announces U S FDA Clearance of Clinical Trial on FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

ASC42 has completed Phase I trials in the U.S. and China. This approval from U.S. FDA enables Gannex to complete a critical drug-drug interaction (DDI) study to support upcoming Phase III trials in China, the U.S. and European Union Gannex expects to complete this DDI study at the beginning of Q4, 2022 Currently, Phase II clinical trial of FXR agonist ASC 42 in China is in progress. Gannex intends to start Phase III clinical trials in China, the U.S. and European Union after the completion of the Phase II clinical trial which is ongoing in China SHANGHAI, June 8, 2022 /PRNewswire/ Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) today announces that it has obtained the U.S. FDA clearance for itsdrug candidate, ASC42, to initiate a drug-drug interaction (DDI) study. This important DDI study is designed to provide more evidence to support upcoming Phase III clinical trials in China, the U.S. and European Union for treatment of primary biliary cholangitis (PBC).

United statesHong kongClin gastroenterol hepatolJinzij wuPrnewswire gannexHong kong stock exchangeEuropean unionAscletis pharma incAscletis pharmaObeticholic acidPrimary biliary cholangitisReduced mortality with treatmentBiliary cholangitisAmerican associationLiver diseasesSc42 has completed phasei trials in the us and china this approval from fda enables gannex to completea critical drug interaction ddi study support upcoming phase iii

Gannex Announces U S FDA Clearance of Clinical Trial on FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

ASC42 has completed Phase I trials in the U.S. and China. This approval from U.S. FDA enables Gannex to complete a critical drug-drug interaction (DDI).

United statesHong kongClin gastroenterol hepatolJinzij wuPrnewswire gannexHong kong stock exchangeEuropean unionAscletis pharma incAscletis pharmaObeticholic acidPrimary biliary cholangitisReduced mortality with treatmentBiliary cholangitisAmerican associationLiver diseasesAscletis pharma inc